Celsius Therapeutics
May 17, 2018
Business Cocktail
Zymeworks Daiichi I-O deal could potentially be worth USD 485 million Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains. The pair is now entering into a new license agreement with a potential deal worth of around USD 484.7 million....
Read More...
-Agonist.png "Toll-like Receptors Agonist")
